Confirm MS and exclude important mimics
The diagnostic pathway combines clinical history and neurological examination with MRI and, when relevant, cerebrospinal-fluid and laboratory findings. A specialist review is particularly useful when imaging is atypical, the diagnosis was made from limited evidence or another inflammatory CNS disease remains possible.
- Brain and spinal MRI review when clinically appropriate
- Clinical history of relapses and neurological deficits
- Cerebrospinal-fluid findings when available or indicated
- Laboratory testing guided by the differential diagnosis
- Review for NMOSD, MOGAD and other inflammatory, infectious, vascular or metabolic mimics
- Assessment of current disability and disease activity
Disease-modifying therapy is individualized
Modern MS care includes multiple disease-modifying therapies with different efficacy, safety, monitoring, pregnancy and infection considerations. A specialist center should review disease activity, previous relapses and MRI change, prior treatment response, comorbidities and patient preferences before starting, switching or escalating therapy.
Relapse treatment and long-term disease control are different questions
High-dose corticosteroids or other acute relapse treatments may be used for selected clinically significant relapses, but treating one relapse is not the same as choosing long-term disease-modifying therapy. The longer-term strategy aims to reduce future inflammatory activity and disability accumulation.
Symptoms and rehabilitation remain part of MS care
Fatigue, spasticity, gait impairment, pain, bladder dysfunction, mood symptoms, cognition and other problems may require separate treatment even when inflammatory disease activity is controlled. Physiotherapy, occupational therapy and neurorehabilitation can therefore be part of the overall pathway.
Pregnancy, vaccination and infection risk can affect treatment decisions
Some disease-modifying therapies require specific planning around conception, pregnancy, breastfeeding, vaccination or infection risk. Specialist centers should coordinate these issues with the patient’s ongoing neurologist rather than interrupting treatment solely for travel convenience.
What to send for an international MS second opinion
A useful review requires the evidence behind the diagnosis and treatment course, not only the label 'multiple sclerosis'.
- Neurology reports and timeline of suspected relapses
- MRI images in original format when requested plus radiology reports
- CSF and laboratory results
- Current and previous disease-modifying therapies with dates
- Reasons for stopping or switching previous treatments
- Current neurological symptoms and disability
- Pregnancy plans or major infection/immunization issues when relevant
Official sources
Sources last checked 2026-08-31. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- 2026 S2k Living Guideline: MS, NMOSD and MOGAD — AWMF / Deutsche Gesellschaft für Neurologie ↗
- Multiple Sclerosis Center — Charité – Universitätsmedizin Berlin ↗
- Neuroimmunology clinic for inflammatory CNS diseases — University Medical Center Freiburg ↗
- Neurology treatment spectrum and recognised MS center — Heidelberg University Hospital ↗